Indole alkaloids

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Retrieved on: 
Tuesday, July 27, 2021
Psychoactive drugs, Entheogens, Branches of biology, NMDA receptor antagonists, Indole alkaloids, Drug rehabilitation, Ibogaine, Tabernanthe iboga, Legal status of ibogaine by country

During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.

Key Points: 
  • During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.
  • As first announced on July 13, 2021, MINDCURE has also filed patent applications for two routes of chemical synthesis of ibogaine.
  • Ibogaine is a psychoactive substance that can be found naturally in the roots of the iboga tree, which grows in Africa.
  • "We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

Retrieved on: 
Tuesday, July 13, 2021
Psychoactive drugs, Branches of biology, Entheogens, Drugs, NMDA receptor antagonists, Indole alkaloids, Ibogaine, Tryptamines, Tabernanthe iboga, Psychedelic drug, Psychedelic therapy, Organic chemistry

The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.

Key Points: 
  • The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.
  • The identified routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds.
  • The two chemical synthesis routes are currently being assessed to determine which one will be selected for further development first.
  • "Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy.

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Retrieved on: 
Thursday, June 3, 2021
Entheogens, Psychoactive drugs, Branches of biology, Drugs, Drug rehabilitation, Nicotinic antagonists, Indole alkaloids, NMDA receptor antagonists, Ibogaine, Tabernanthe iboga, Pharmaceutical industry, Synthetic

Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.

Key Points: 
  • Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.
  • In the coming weeks, MINDCURE will focus on the scale-up process by launching stage two of the manufacturing process for pharmaceutical grade ibogaine.
  • By manufacturing synthetic ibogaine, MINDCURE's research team will have access to a sustainable and high-quality drug supply, ensuring consistent dosing and reliable results.
  • "We have successfully completed the critical first step in our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

Ibogaine by David Dardashti Recommends Ibogaine Treatments to be Tailored to Individuals

Retrieved on: 
Friday, April 9, 2021
Psychoactive drugs, Entheogens, Branches of biology, Drugs, NMDA receptor antagonists, Indole alkaloids, Drug rehabilitation, Nicotinic antagonists, Ibogaine, Tabernanthe iboga, Howard Lotsof

Ibogaine hydrochloride has proven to be the most effective treatment for opiate addiction, yet complications still arise.

Key Points: 
  • Ibogaine hydrochloride has proven to be the most effective treatment for opiate addiction, yet complications still arise.
  • They simply have a one size fits all method of Ibogaine treatment.
  • Ibogaine By David Dardashti has worked many years providing the most effective full treatment of ibogaine hydrochloride, having treated thousands of patients.
  • Ibogaine By David Dardashti has integrated many mathematical models, using principles of calculus, algebra, and statistics, used to effectively measure and predict the outcome of a single person's reaction to the ibogaine.

American Kratom Association: HHS Rescinds Scheduling Recommendation For Kratom But FDA Failed To Notify The Public For 2 ½ Years

Retrieved on: 
Thursday, January 28, 2021
Opioids, Indole alkaloids, Organic compounds, Psychoactive drugs, Antidiarrhoeals, Euphoriants, Mitragyna speciosa, Drugs, Mitragynine, 7-Hydroxymitragynine

In the HHS letter to the Drug Enforcement Administration (DEA) HHS recommended that "mitragynine and 7-hydroxymitragynine not be controlled at this time, either temporarily or permanently, until scientific research can sufficiently support such an action."

Key Points: 
  • In the HHS letter to the Drug Enforcement Administration (DEA) HHS recommended that "mitragynine and 7-hydroxymitragynine not be controlled at this time, either temporarily or permanently, until scientific research can sufficiently support such an action."
  • HHS concluded that "there is a significant risk of immediate adverse public health consequences to potentially millions of users if kratom or its components are included in Schedule I."
  • The HHS letter outlined 5 specific criteria for "further analysis and public input regarding kratom" before any scheduling should be undertaken.
  • Since the issuance of the recission letter, additional compelling research has further undermined the FDA's claims on the safety and abuse potential for kratom.

ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse

Retrieved on: 
Thursday, July 9, 2020
Psychoactive drugs, Euphoriants, Analgesics, Opioids, Organic compounds, RTT, Ethers, Indole alkaloids, Mitragynine

Additionally, Srinivas Rao, MD, PhD, Chief Scientific Officer of ATAI Life Sciences, has been appointed CEO of Kures.

Key Points: 
  • Additionally, Srinivas Rao, MD, PhD, Chief Scientific Officer of ATAI Life Sciences, has been appointed CEO of Kures.
  • Both mitragynine and KUR-101 are atypical opioid receptor modulators, boasting unique pharmacology that may make them safer than currently available opioids in treating pain.
  • Moreover, it is estimated that 8-12% of individuals prescribed opioids for chronic pain ultimately develop opioid use disorder.
  • "Kures is excited to have the resources and commitment of ATAI in advancing our promising therapeutic compounds," added Andrew Kruegel, CSO and co-founder of Kures.